All patients
Age < 65y (younger) Age > 65y Age > 75y (older) BRAF mutant BRAF wild type ECOG ⩾ 1 ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PD-L1 < 1% PD-L1 < 5% PD-L1 > 1% PD-L1 > 5% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) Prior anti-CTLA4 benefit NO Prior anti-CTLA4 benefit YES stage III (locally advanced) stage IIIc stage IV (metastatic) stage M0 stage M0/M1A/M1B stage M1A stage M1B stage M1C
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
mML - 1st line (L1), immune chekpoint inhibitors vs. anti-PD-(L)1, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 067 (N vs I ; all population), 2015 0.63 [0.48; 0.82]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 0.65 [0.53; 0.80]
IMspire-170, 2020 1.06 [0.69; 1.62]
0.72 [0.56 ; 0.92 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, IMspire-170, 2020 3 58% 1,707 low not evaluable deaths (OS) (extension)detailed results CheckMate 067 (N vs I ; all population), 2015 0.63 [0.52; 0.76]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 0.83 [0.67; 1.03]
0.72 [0.55 ; 0.94 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 72% 1,261 low not evaluable PFS (extension)detailed results CheckMate 067 (N vs I ; all population), 2015 0.53 [0.44; 0.64]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 0.79 [0.65; 0.97]
0.65 [0.44 ; 0.95 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 88% 1,261 low not evaluable progression or deaths (PFS)detailed results CheckMate 067 (N vs I ; all population), 2015 0.57 [0.43; 0.76]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 0.74 [0.60; 0.92]
IMspire-170, 2020 1.15 [0.88; 1.50]
0.79 [0.54 ; 1.14 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, IMspire-170, 2020 3 85% 1,707 low not evaluable DCRdetailed results IMspire-170, 2020 0.91 [0.63; 1.32]
0.91 [0.63 ; 1.32 ] IMspire-170, 2020 1 0% 446 NA not evaluable objective responses (ORR)detailed results CheckMate 067 (N vs I ; all population), 2015 3.40 [2.02; 5.72]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.76 [1.28; 2.41]
IMspire-170, 2020 0.77 [0.50; 1.17]
1.64 [0.77 ; 3.49 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, IMspire-170, 2020 3 90% 1,707 low not evaluable objective responses (ORR) (extension)detailed results CheckMate 067 (N vs I ; all population), 2015 3.54 [2.46; 5.10]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 5.96 [4.16; 8.54]
4.60 [2.76 ; 7.66 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 75% 1,261 low not evaluable AE (any grade)detailed results IMspire-170, 2020 14.27 [3.34; 61.03]
14.27 [3.34 ; 61.03 ] IMspire-170, 2020 1 0% 436 NA not evaluable AE (grade 3-4)detailed results IMspire-170, 2020 4.03 [2.70; 6.00]
4.03 [2.70 ; 6.00 ] IMspire-170, 2020 1 0% 436 NA not evaluable AE leading to death (grade 5)detailed results IMspire-170, 2020 1.39 [0.43; 4.44]
1.39 [0.43 ; 4.44 ] IMspire-170, 2020 1 0% 436 NA not evaluable TRAE (any grade)detailed results CheckMate 067 (N vs I ; all population), 2015 1.01 [0.64; 1.59]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.58 [1.88; 6.81]
1.86 [0.54 ; 6.43 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 90% 1,250 low not evaluable TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.71 [0.49; 1.03]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 4.82 [3.41; 6.80]
1.85 [0.29 ; 12.06 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 98% 1,250 low not evaluable TRAE leading to death (grade 5)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.00 [0.02; 50.56]
1.00 [0.06 ; 15.97 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 0% 1,250 low not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 067 (N vs I ; all population), 2015 0.72 [0.45; 1.13]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 4.85 [3.25; 7.24]
1.87 [0.29 ; 12.18 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 97% 1,250 low not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.52 [0.31; 0.88]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 5.10 [3.17; 8.19]
1.63 [0.17 ; 15.32 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 98% 1,250 low not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.25 [0.01; 5.50]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 2.00 [0.07; 59.93]
0.64 [0.06 ; 6.33 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 0% 1,250 low not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.18; 22.10]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.04 [0.61; 15.17]
2.67 [0.70 ; 10.16 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 0% 1,250 low not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 2.01 [0.18; 22.24]
2.00 [0.28 ; 14.26 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 0% 1,250 low not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.04; 5.49]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.00 [0.06; 16.06]
0.67 [0.11 ; 4.12 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 0% 1,250 low not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.12 [0.03; 0.39]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 9.36 [2.80; 31.26]
1.04 [0.01 ; 77.14 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 96% 1,250 low not evaluable Cough TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 3.99 [0.18; 88.92]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 0.25 [0.01; 5.54]
1.00 [0.07 ; 15.14 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 35% 1,250 low not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 8.09 [0.43; 153.69]
2.29 [0.15 ; 34.90 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 32% 1,250 low not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.48 [0.21; 1.09]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.45 [1.60; 7.41]
1.30 [0.19 ; 8.92 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 92% 1,250 low not evaluable Dry skin TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.00 [0.02; 50.56]
1.00 [0.06 ; 15.97 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 0% 1,250 low not evaluable Dyspnoea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.02 [0.31; 29.19]
2.66 [0.40 ; 17.52 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 0% 1,250 low not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.20; 4.96]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 4.48 [1.26; 15.87]
2.30 [0.53 ; 9.95 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 52% 1,250 low not evaluable Headache TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 4.02 [0.18; 89.49]
1.55 [0.16 ; 15.35 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 0% 1,250 low not evaluable Hepatitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 10.15 [0.55; 186.51]
4.45 [0.43 ; 46.06 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 0% 1,250 low not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 6.05 [0.30; 121.25]
3.11 [0.29 ; 33.65 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 0% 1,250 low not evaluable Hypophysitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.20 [0.02; 1.69]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 5.06 [0.59; 43.61]
1.00 [0.04 ; 24.12 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 77% 1,250 low not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 2.00 [0.07; 59.93]
1.48 [0.11 ; 19.35 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 0% 1,250 low not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.50 [0.25; 9.01]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 6.68 [1.96; 22.80]
3.67 [0.87 ; 15.44 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 45% 1,250 low not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.79 [0.21; 2.98]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 7.29 [2.52; 21.10]
2.49 [0.28 ; 21.93 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 85% 1,250 low not evaluable Increased lipase level TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.17 [0.53; 2.56]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 2.60 [1.37; 4.95]
1.80 [0.82 ; 3.94 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 58% 1,250 low not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.18; 22.10]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.04 [0.61; 15.17]
2.67 [0.70 ; 10.16 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 0% 1,250 low not evaluable Myalgia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.00 [0.06; 16.06]
1.32 [0.15 ; 11.31 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 0% 1,250 low not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.25 [0.01; 5.50]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 14.30 [0.81; 253.04]
1.96 [0.04 ; 104.67 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 72% 1,250 low not evaluable Pneumonitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.06; 15.96]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.02 [0.31; 29.19]
1.93 [0.33 ; 11.21 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 0% 1,250 low not evaluable Pruritic rash TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.00 [0.02; 50.56]
1.00 [0.06 ; 15.97 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 0% 1,250 low not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.06; 15.96]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 6.10 [0.73; 50.95]
3.10 [0.55 ; 17.30 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 3% 1,250 low not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 4.02 [0.18; 89.49]
1.55 [0.16 ; 15.35 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 0% 1,250 low not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.20 [0.02; 1.69]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 10.30 [1.31; 80.93]
1.44 [0.03 ; 69.79 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 85% 1,250 low not evaluable Thyroiditis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 2.00 [0.07; 59.93]
1.48 [0.11 ; 19.35 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 0% 1,250 low not evaluable Vitiligo TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 0.50 [0.02; 14.93]
1.00 [0.09 ; 11.02 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 0% 1,250 low not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.06; 15.96]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 7.14 [0.87; 58.36]
3.31 [0.50 ; 21.79 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 19% 1,250 low not evaluable Weight decreased TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.00 [0.02; 50.56]
0.67 [0.05 ; 8.74 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 2 0% 1,250 low not evaluable Abdominal pain AE (grade 3-4)detailed results IMspire-170, 2020 0.98 [0.14; 7.03]
0.98 [0.14 ; 7.03 ] IMspire-170, 2020 1 0% 436 NA not evaluable Anaemia AE (grade 3-4)detailed results IMspire-170, 2020 1.74 [0.50; 6.04]
1.74 [0.50 ; 6.04 ] IMspire-170, 2020 1 0% 436 NA not evaluable Arthralgia AE (grade 3-4)detailed results IMspire-170, 2020 0.98 [0.02; 49.71]
0.98 [0.02 ; 49.71 ] IMspire-170, 2020 1 0% 436 NA not evaluable Asthenia AE (grade 3-4)detailed results IMspire-170, 2020 1.74 [0.50; 6.04]
1.74 [0.50 ; 6.04 ] IMspire-170, 2020 1 0% 436 NA not evaluable Constipation AE (grade 3-4)detailed results IMspire-170, 2020 0.98 [0.02; 49.71]
0.98 [0.02 ; 49.71 ] IMspire-170, 2020 1 0% 436 NA not evaluable Decreased appetite AE (grade 3-4)detailed results IMspire-170, 2020 1.97 [0.07; 58.97]
1.97 [0.07 ; 58.97 ] IMspire-170, 2020 1 0% 436 NA not evaluable Dermatitis acneiform AE (grade 3-4)detailed results Out of scale IMspire-170, 2020 22.68 [1.32; 388.47]
22.68 [1.32 ; 388.47 ] IMspire-170, 2020 1 0% 436 NA not evaluable Diarrhoea AE (grade 3-4)detailed results IMspire-170, 2020 4.44 [1.47; 13.42]
4.44 [1.47 ; 13.42 ] IMspire-170, 2020 1 0% 436 NA not evaluable Fatigue AE (grade 3-4)detailed results IMspire-170, 2020 1.65 [0.39; 7.00]
1.65 [0.39 ; 7.00 ] IMspire-170, 2020 1 0% 436 NA not evaluable Headache AE (grade 3-4)detailed results IMspire-170, 2020 1.97 [0.07; 58.97]
1.97 [0.07 ; 58.97 ] IMspire-170, 2020 1 0% 436 NA not evaluable Hypertension AE (grade 3-4)detailed results IMspire-170, 2020 1.77 [0.73; 4.30]
1.77 [0.73 ; 4.30 ] IMspire-170, 2020 1 0% 436 NA not evaluable Increase AST AE (grade 3-4)detailed results IMspire-170, 2020 3.00 [0.60; 15.03]
3.00 [0.60 ; 15.03 ] IMspire-170, 2020 1 0% 436 NA not evaluable Increased ALT AE (grade 3-4)detailed results IMspire-170, 2020 1.99 [0.49; 8.06]
1.99 [0.49 ; 8.06 ] IMspire-170, 2020 1 0% 436 NA not evaluable Increased Lipase Level AE (grade 3-4)detailed results IMspire-170, 2020 2.00 [0.59; 6.74]
2.00 [0.59 ; 6.74 ] IMspire-170, 2020 1 0% 436 NA not evaluable Nausea AE (grade 3-4)detailed results IMspire-170, 2020 10.02 [0.54; 184.60]
10.02 [0.54 ; 184.60 ] IMspire-170, 2020 1 0% 436 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results IMspire-170, 2020 0.98 [0.06; 15.80]
0.98 [0.06 ; 15.80 ] IMspire-170, 2020 1 0% 436 NA not evaluable Pruritus AE (grade 3-4)detailed results IMspire-170, 2020 0.98 [0.02; 49.71]
0.98 [0.02 ; 49.71 ] IMspire-170, 2020 1 0% 436 NA not evaluable Pyrexia AE (grade 3-4)detailed results IMspire-170, 2020 6.03 [0.72; 50.50]
6.03 [0.72 ; 50.50 ] IMspire-170, 2020 1 0% 436 NA not evaluable Rash AE (grade 3-4)detailed results IMspire-170, 2020 7.83 [1.77; 34.66]
7.83 [1.77 ; 34.66 ] IMspire-170, 2020 1 0% 436 NA not evaluable Rash maculopapular AE (grade 3-4)detailed results IMspire-170, 2020 7.98 [0.42; 151.89]
7.98 [0.42 ; 151.89 ] IMspire-170, 2020 1 0% 436 NA not evaluable Sepsis AE (grade 3-4)detailed results IMspire-170, 2020 12.08 [0.67; 217.70]
12.08 [0.67 ; 217.70 ] IMspire-170, 2020 1 0% 436 NA not evaluable Vomiting AE (grade 3-4)detailed results IMspire-170, 2020 2.49 [0.48; 12.97]
2.49 [0.48 ; 12.97 ] IMspire-170, 2020 1 0% 436 NA not evaluable 0.2 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-07-01 16:17 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 285,68,127,128
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,746,745,856,634,861,416,864,769,980,369,743
